Alterity Therapeutics (ATHE) Operating Leases (2019 - 2026)

Alterity Therapeutics has reported Operating Leases for 8 years, with the latest figure at $39138.6 in Q2 2026.

• On a quarterly basis, Operating Leases fell 8.67% year-over-year to $39138.6 in Q2 2026; TTM through Jun 2026 was $39138.6, a 8.67% decrease from a year earlier, with the FY2026 full-year figure at $39138.6, down 8.67% from the prior year.
• Operating Leases was $39138.6 for Q2 2026 at Alterity Therapeutics, up from $21659.1 in the prior quarter.
• The five-year high for Operating Leases was $42873.7 in Q2 2022, with the low at $1071.3 in Q2 2024.
• Average Operating Leases over 5 years is $24777.9, with a median of $30398.8 recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Operating Leases slumped 97.5% in 2023, then surged 3900.02% in 2025.
• Over 5 years, Operating Leases stood at $42873.7 in 2022, then plunged by 97.5% to $1071.8 in 2023, then fell by 0.04% to $1071.3 in 2024, then jumped by 1921.74% to $21659.1 in 2025, then soared by 80.7% to $39138.6 in 2026.
• The last three Operating Leases figures came in at $39138.6 (Q2 2026), $21659.1 (Q4 2025), and $42852.7 (Q2 2025), per Business Quant data.